Skye Bioscience will present its obesity treatment candidate nimacimab at the GLP-1-Based Therapeutics Summit in Boston on April 16, 2026. Nimacimab is a novel antibody designed to block the CB1 receptor outside the brain, potentially avoiding neuropsychiatric side effects seen in previous drugs. It is being developed to complement GLP-1 agonists like semaglutide, aiming to enhance weight loss and reduce weight regain without added side effects. Skye is currently conducting Phase 2a trials and plans to explore higher dosing and combination therapies to improve obesity treatment outcomes.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
